- ION582 demonstrated consistent improvements across multiple functional domains in Angelman syndrome patients
- ION582 was safe and well tolerated at all dose levels
- Ionis plans to move ION582 into pivotal trial
- Detailed ION582 data to be presented at upcoming medical meeting
Ionis Pharmaceuticals Announced Topline Data From HALOS Phase 1/2A Open-label Study Of ION582 In Angelman Syndrome, ION582 Was Safe And Well Tolerated In The Study And Showed Encouraging And Consistent Benefits
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.